retatrutide ly3437943 triple agonist glp-1 gip glucagon Research Peptide Australia | GLP-1/GIP/Glucagon Retatrutide Guide 2023: Weight Loss,
Description
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach
Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results
Obesity and type 2 diabetes (T2D) are associated with increased rates of mental disorders, particularly depression, anxiety and binge-eating disorder
Participation in this program does not replace healthy lifestyle habits, including balanced nutrition and regular movement
Injection-site reactions and worsening of pre-existing diabetic retinopathy are also relevant clinical concerns
WHO Guidelines
